Mesoblast Limited announced that Philip R. Krause, M.D. has joined its Board of Directors. Dr. Krause was for the past decade Deputy Director, Office of Vaccines Research and Review (OVRR) at the US Food and Drug Administration (FDA)'s Center for Biologics Evaluation and Research (CBER). Dr. Krause is currently Chair of the World Health Organization COVID Vaccines Research Expert Group, and most recently he shared responsibility for regulatory authorizations of COVID-19 vaccines in the US.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.11 AUD | -.--% | -5.53% | +258.06% |
May. 01 | Mesoblast Limited Announces Board and Committee Changes | CI |
Apr. 01 | ADRs End Higher; Connect Biopharma Climbs 26% | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+258.06% | 842M | |
+43.36% | 58.06B | |
-5.31% | 40.53B | |
+37.52% | 38.99B | |
+14.75% | 26.7B | |
-12.56% | 26.56B | |
-22.45% | 18.98B | |
+0.04% | 12.17B | |
+25.12% | 12B | |
+26.04% | 11.92B |
- Stock Market
- Equities
- MSB Stock
- News Mesoblast Limited
- Mesoblast Limited Appoints Philip R. Krause to its Board of Directors